Mohler Peter J, Splawski Igor, Napolitano Carlo, Bottelli Georgia, Sharpe Leah, Timothy Katherine, Priori Silvia G, Keating Mark T, Bennett Vann
Howard Hughes Medical Institute and Department of Cell Biology, Duke University Medical Center, Durham, NC 27710, USA.
Proc Natl Acad Sci U S A. 2004 Jun 15;101(24):9137-42. doi: 10.1073/pnas.0402546101. Epub 2004 Jun 3.
220-kDa ankyrin-B is required for coordinated assembly of Na/Ca exchanger, Na/K ATPase, and inositol trisphosphate (InsP(3)) receptor at transverse-tubule/sarcoplasmic reticulum sites in cardiomyocytes. A loss-of-function mutation of ankyrin-B identified in an extended kindred causes a dominantly inherited cardiac arrhythmia, initially described as type 4 long QT syndrome. Here we report the identification of eight unrelated probands harboring ankyrin-B loss-of-function mutations, including four previously undescribed mutations, whose clinical features distinguish the cardiac phenotype associated with loss of ankyrin-B activity from classic long QT syndromes. Humans with ankyrin-B mutations display varying degrees of cardiac dysfunction including bradycardia, sinus arrhythmia, idiopathic ventricular fibrillation, catecholaminergic polymorphic ventricular tachycardia, and risk of sudden death. However, a prolonged rate-corrected QT interval was not a consistent feature, indicating that ankyrin-B dysfunction represents a clinical entity distinct from classic long QT syndromes. The mutations are localized in the ankyrin-B regulatory domain, which distinguishes function of ankyrin-B from ankyrin-G in cardiomyocytes. All mutations abolish ability of ankyrin-B to restore abnormal Ca(2+) dynamics and abnormal localization and expression of Na/Ca exchanger, Na/K ATPase, and InsP(3)R in ankyrin-B(+/-) cardiomyocytes. This study, considered together with the first description of ankyrin-B mutation associated with cardiac dysfunction, supports a previously undescribed paradigm for human disease due to abnormal coordination of multiple functionally related ion channels and transporters, in this case the Na/K ATPase, Na/Ca exchanger, and InsP(3) receptor.
220-kDa锚蛋白B是心肌细胞横管/肌浆网部位钠钙交换体、钠钾ATP酶和肌醇三磷酸(InsP(3))受体协同组装所必需的。在一个大家族中鉴定出的锚蛋白B功能丧失突变导致一种显性遗传的心律失常,最初被描述为4型长QT综合征。在此,我们报告鉴定出8名携带锚蛋白B功能丧失突变的无关先证者,包括4个先前未描述的突变,其临床特征将与锚蛋白B活性丧失相关的心脏表型与经典长QT综合征区分开来。携带锚蛋白B突变的人类表现出不同程度的心脏功能障碍,包括心动过缓、窦性心律失常、特发性心室颤动、儿茶酚胺能多形性室性心动过速和猝死风险。然而,校正心率后的QT间期延长并非一致特征,这表明锚蛋白B功能障碍代表一种与经典长QT综合征不同的临床实体。这些突变定位于锚蛋白B调节域,这在心肌细胞中区分了锚蛋白B与锚蛋白G的功能。所有突变均消除了锚蛋白B恢复锚蛋白B(+/-)心肌细胞中异常钙动力学以及钠钙交换体、钠钾ATP酶和InsP(3)R异常定位和表达的能力。这项研究,连同对与心脏功能障碍相关的锚蛋白B突变的首次描述,支持了一种先前未描述的人类疾病范式,即由于多种功能相关离子通道和转运体的异常协调,在这种情况下是钠钾ATP酶、钠钙交换体和InsP(3)受体。